Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Lianlu Industrial is a China-based manufacturer of pharmaceutical and nutraceutical ingredients rather than a drug-development biotech. Founded in 2011, the company integrates R&D, manufacturing, sales, and import/export, with operations centered on vitamin derivatives, pyruvic acid and its salts, pharmaceutical intermediates, and steroid-related products. Its wholly owned subsidiaries include Shanghai New Sunow Chemical as an R&D center and Jiangxi Lianlu Bio-Technology as a manufacturing base. The company appears to operate commercial production facilities, including GMP-compliant manufacturing capacity for ingredient production and OEM/ODM dosage-form services such as tablets, capsules, coatings, and premixes. It is listed on China’s National Equities Exchange and Quotations system under the stock code 838502.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Lianlu Industrial.